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Introduction
Patients	 with	 the	 acute	 coronary	 syndrome	
often	 have	 ruptured	 atherosclerotic	
plaques,	 which	 could	 lead	 to	 platelet	
activation	 and	 coronary	 obstruction	
secondary	 to	 thrombosis.	 Antiplatelet	
drugs	 often	 reduce	 mortal	 complications.	
In	 these	 patients,	 coronary	 artery	 bypass	
graft	 surgery	 (CABG)	 is	 imperative	 for	
revascularization.[1,2]	 Although	 antiplatelet	
drugs	 such	 as	 aspirin	 are	 well	 known	
for	 primary	 and	 secondary	 prevention	 in	
coronary	 artery	 disease,[3]	 the	 increasing	
prevalence	of	postoperative	bleeding	 is	 still	
a	 concern.[4]	 Newly	 introduced	 antiplatelet	
drugs	 such	 as	 clopidogrel,	 prasugrel,	 and	
ticagrelor	 have	 conferred	 similar	 relative	
benefits	among	these	patients.
Clopidogrel	 (Plavix®)	 is	 a	 drug	 with	
selective	 and	 irreversible	 inhibition	 of	 the	
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Abstract
Background:	 The	 aim	 of	 the	 present	 study	 was	 to	 investigate	 the	 relationship	 between	 maximum	
clot	 firmness	 (MCF)	 in	 rotational	 thromboelastometry	 (ROTEM®)	 and	 postoperative	 bleeding	 in	
patients	 on	 clopidogrel	 after	 emergency	 coronary	 artery	 bypass	 graft	 surgery	 (CABG).	 Methods: 
This	 observational	 study	 recruited	 60	 patients	 posted	 for	 emergency	CABG	 following	 unsuccessful	
primary	 percutaneous	 coronary	 intervention	 (PCI)	 while	 on	 600	 mg	 of	 clopidogrel.	 The	 study	
population	 was	 divided	 into	 2	 groups	 on	 the	 basis	 of	 their	 MCF	 in	 the	 extrinsically	 activated	
thromboelastometric	 (EXTEM)	 component	 of	 the	 (preoperative)	 ROTEM®	 test:	 patients	 with	
MCF	<50	mm	 (n	 =	 16)	 and	 those	with	MCF	≥50	mm	 (n	 =	 44).	 Postoperative	 chest	 tube	 drainage	
amount,	need	for	blood	product	transfusion,	postoperative	complications,	and	duration	of	mechanical	
ventilation	 after	 CABG	were	 recorded.	Results:	 No	 significant	 differences	 were	 observed	 between	
the	 two	groups	 regarding	duration	of	surgery,	cardiopulmonary	bypass,	and	aortic	cross‑clamp	 time.	
Chest	 tube	drainage	at	6,	12,	and	24	h	after	Intensive	Care	Unit	admission	were	significantly	higher	
in	 the	 patients	with	MCF	below	50	mm.	The	 need	 for	 blood	 product	 transfusion	was	 higher	 in	 the	
group	with	MCF	<50	mm.	In	patients	who	experienced	postoperative	bleeding	of	1000	mL	or	more,	
the	ROTEM®	parameters	of	INTEM	(Intrinsically	activated	thromboelastomery)	α	and	MCF,	EXTEM	
α	 and	 MCF,	 and	 HEPTEM	 (INTEM	 assay	 performed	 in	 the	 presence	 of	 heparinase)	 MCF	 (but	
not 	 FIBTEM	 (Thromboelastometric	 assay	 for	 the	 fibrin	 part	 of	 the	 clot)	 values)	 were	 significantly	
lower	 than	 those	 with	 postoperative	 bleeding	 <1000	 mL	 (P	 ≤	 0.05).	 Conclusions:	 When	 platelet	
aggregometry	 is	not	available,	 the	ROTEM®	 test	could	be	useful	for	 the	prediction	of	 increased	risk	
bleeding	after	emergency	CABG	in	patients	who	have	received	a	loading	dose	of	clopidogrel.
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to	 its	 receptor.[5]	 Given	 its	 antiplatelet	
properties,	 the	 combination	 of	 clopidogrel	
with	 aspirin	 contributes	 to	 maintain	
patency	 of	 stents.[6]	 Moreover,	 this	 drug	 is	
used	 in	 carotid	 and	 peripheral	 stenosis	 as	
well.[7]	 Many	 patients	 with	 intracoronary	
stents	 benefit	 from	 the	 antiplatelet	
properties	 of	 clopidogrel.	 However,	 risk	 of	
postoperative	bleeding	and	need	for	surgical	
re‑exploration	 have	 been	 increasingly	
reported	 in	 these	 patients.[8‑11]	 Despite	
the	 recent	 rise	 in	 the	 perioperative	 use	 of	
clopidogrel,	 literature	 contains	 conflicting	
reports	 on	 the	 results.	 A	 study	 suggested	
that	 clopidogrel	 consumption	 in	 a	 period	
of	 5	 days	 preceding	 surgery	 could	 increase	
morbidity	 and	mortality,	 and	 if	 used	 in	 the	
preceding	 48	 h,	 it	 might	 increase	 the	 risk	
of	 postoperative	 bleeding.[8]	 Another	 study	
showed	 that	clopidogrel	used	4	days	before	
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surgery	increased	the	risk	of	bleeding,	blood	transfusion,	and	
duration	 of	 Intensive	 Care	 Unit	 (ICU)	 stay.[12]	 Conversely,	
a	 clinical	 trial	 carried	 out	 on	 106	 patients	 showed	 that	
clopidogrel	only	slightly	 increased	 the	risk	of	bleeding	and	
concluded	 that	 the	 advantages	 of	 clopidogrel	 outweighed	
its	 side	 effects.[13]	 Clopidogrel	 has	 irreversible	 effects	 on	
platelet	 function.[14,15]	 Some	 studies	 have	 suggested	 that	
the	 drug	 be	 discontinued	 5	 days	 preceding	 surgery,[16]	
whereas	 others	 have	 maintained	 that	 a	 7‑day	 period	 is	
safe.[17]	 Rotational	 thromboelastometry	 (ROTEM®)	 is	
drawn	 upon	 for	 viscoelastic	 diagnosis	 and	 noninvasive	
measurement	 of	 the	 hemostatic	 and	 coagulopathy	 state,	
degree	 of	 lysis,	 and	 platelet	 dysfunction.[18]	 ROTEM®	
represents	 an	 efficient	 evaluation	 for	 the	 hemostatic	 state	
of	 the	 clot.[19]	 Patients	 with	 abnormal	 ROTEM®	 exhibit	 a	
high	 incidence	 rate	 of	 postoperative	 bleeding[20]	 and	 the	
use	 of	 ROTEM®	 intraoperatively	 reduces	 the	 need	 for	
blood	 transfusion.[21]	 One	 of	 the	 usual	 tests	 employed	 for	
the	 evaluation	 of	 platelet	 activity	 is	 multiple	 electrode	
aggregometry	 using	 a	 Multiplate®	 analyzer.	 Although	
this	 technique	 has	 long	 been	 applied	 in	 interventional	
cardiology	 to	 evaluate	 the	 result	 of	 antiplatelet	 therapy,	
it	 is	 not	 available	 at	 departments	 of	 cardiac	 surgery	 as	 a	
standard	 assessment	 tool.[22]	 When	 platelet	 aggregometry	
is	 not	 available,	 patients	 posted	 for	 emergency	 CABG	
on	 full‑dose	 clopidogrel	 following	 failed	 percutaneous	
coronary	intervention	(PCI)	may	benefit	from	the	ROTEM®	
test	insofar	as	it	can	help	to	evaluate	the	coagulation	status,	
to	 provide	 information	 on	 the	 increased	 risk	 of	 bleeding,	
and	to	determine	transfusion	requirements.
The	 present	 study	 was	 designed	 to	 evaluate	 the	 role	 of	
the	 ROTEM®	 test	 parameters	 such	 as	 maximum	 clot	
firmness	(MCF)	in	the	prediction	of	bleeding	postemergency	
CABG,	in	patients	on	clopidogrel.
Methods
In	this	observational	study,	60	patients	aged	between	18	and	
85	years	who	were	posted	for	emergency	CABG	following	
unsuccessful	 primary	 PCI	 who	 had	 been	 administered	
600	 mg	 loading	 dose	 of	 clopidogrel	 were	 assigned	 to	
2	 groups	 on	 the	 basis	 of	 their	 MCF	 in	 the	 extrinsically	
activated	 thromboelastometric	 (EXTEM)	 assessment	 of	
the	 ROTEM®	 test.	 The	 time	 interval	 between	 PCI	 and	
CABG	was	between	6	 and	24	h.	The	ROTEM®	 tests	were	
conducted	 when	 consultations	 were	 sent	 for	 emergent	
CABG.	We	chose	“50	mm”	for	the	minimum	normal	value	
of	 EXTEM	MCF	 as	 our	 study	 cutoff	 point	 to	 divide	 our	
patients	into	two	groups:	those	with	MCF	<50	mm	(n	=	16)	
and	 those	 with	 MCF	 ≥50	 mm	 (n	 =	 44).	 The	 study	 was	
approved	 by	 the	 local	 ethics	 committee	 and	 informed	
consent	was	obtained	from	all	the	participating	patients.
Patients	 with	 anemia	 with	 hematocrit	 <30%,	 platelet	
count	 <120000/mL,	 patients	with	 renal	 failure	 (creatinine	
clearance	 <30	 mL/min),	 patients	 with	 active	 liver	
disease,	 and	 patients	 with	 severe	 coagulopathy	 or	 under	
anticoagulation	 (warfarin	 or	 heparin)	 therapy	 before	
surgery	 were	 excluded	 from	 the	 study.	 Demographic	
data	 and	 intraoperative	 values	 were	 recorded	 for	 all	 the	
patients.
The	 ROTEM®	 test	 comprising	 of	 EXTEM,	 INTEM,	
FIBTEM,	 and	HEPTEM	was	 conducted	 for	 all	 the	 patients	
before	surgery.	The	patients	were	given	lorazepam	(1–2	mg)	
as	premedication	on	 the	night	of	 surgery	 and	 intramuscular	
morphine	 sulfate	 (3–5	mg)	 on	 the	 morning	 of	 surgery.	All	
the	patients	received	5–15	cc/kg	body	weight	of	crystalloids	
for	 compensating	 intravascular	 volume	 expansion	 and	 they	
underwent	standard	monitoring	(i.e.	pulse	oximetry,	invasive	
blood	 pressure,	 electrocardiography,	 and	 central	 venous	
pressure	 measurement).	 After	 the	 patients	 were	 given	
5	µg	of	 sufentanil,	 an	arterial	 line	was	placed.	The	patients	
received	 0.1–0.15	 mg/kg	 of	 midazolam,	 1–2	 µg/kg	 of	
sufentanil,	and	0.2	mg/kg	of	cisatracurium	for	the	induction	
of	 anesthesia.	 After	 tracheal	 intubation,	 a	 central	 venous	
line	 was	 placed,	 and	 sufentanil,	 atracurium,	midazolam,	 or	
propofol	were	 used	 for	 the	maintenance	 of	 anesthesia.	The	
cardiopulmonary	bypass	and	surgery	techniques	were	similar	
in	 all	 the	 individuals.	 All	 the	 patients	 were	 transferred	
intubated	 to	 the	 ICU	 after	 surgery.	 The	 cardiac	 surgeons	
who	 evaluated	 postoperative	 drainage	 of	 the	 patients	 were	
not	aware	about	the	values	of	preoperative	ROTEM	test	that	
was	performed	by	the	anesthesiologist.
Drain	 from	 the	 chest	 tube,	 need	 for	 blood	 product	
transfusion,	 cardiac	 (i.e.,	 myocardial	 infarction	 and	
arrhythmia),	 respiratory,	 renal,	 and	 cerebral	 complications,	
tracheal	 intubation	time,	and	ICU	stay	time	were	measured	
and	 recorded	 for	 all	 the	 participants.	 The	 collected	 data	
were	 entered	 into	 IBM	 SPSS®	 Statistics	 for	 Windows,	
version	 20.0	 (IBM	 Corp,	 Armonk,	 NY,	 USA).	 The	
one‑sample	 Kolmogorov–Smirnov	 test	 was	 utilized	 to	
evaluate	the	normal	distribution	of	the	data.	The	Chi‑square	
test	was	applied	for	the	analysis	of	the	categorical	variables	
and	 Mann–Whitney	 U‑test	 for	 the	 statistical	 analysis	
of	 the	 nonparametric	 data.	 In	 addition,	 the	 independent	
samples	 t‑test	was	used	 to	compare	 the	mean	values	of	 the	
continuous	 variables	 between	 the	 study	 groups. P ≤	 0.05	
was	considered	statistically	significant	in	this	study.
Results
As	 is	 shown	 in	 Table	 1,	 the	 demographic	 variables	 and	
the	 surgical	 data	 were	 similar	 in	 both	 groups.	 Concerning	
the	 consumption	 of	 drugs	 such	 as	 nitrates,	 beta‑blockers,	
angiotensin‑converting	 enzyme	 inhibitors,	 aspirin,	
and	 proton	 pump	 inhibitors,	 there	 were	 no	 significant	
differences	 between	 the	 two	 groups.	 The	 laboratory	
parameters,	 recorded	 for	 all	 the	 patients,	 showed	 no	
statistically	significant	difference	between	the	study	groups.	
Table	 2	 summarizes	 the	 complications	 on	 the	 basis	 of	 the	
MCF	 values:	 below	 50	 mm	 and	 ≥50	 mm	 (in	 the	 2	 study	
groups).	No	significant	differences	were	observed	regarding	
cardiopulmonary	 bypass,	 aortic	 cross‑clamp	 time,	 and	
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operation	 times	between	 the	 two	groups.	The	measurement	
of	 chest	 tube	 drainage	 amounts	 at	 6,	 12,	 and	 24	 h	 after	
admission	 to	 the	 ICU	 revealed	 that	 the	values	were	higher	
in	 the	 group	 with	 MCF	 <50	 mm;	 the	 difference	 was	
statistically	significant.
Five	 (31.3%)	 patients	 with	 MCF	 below	 50	 mm	
needed	 surgical	 re‑exploration,	 while	 there	 were	 only	
4	 (6.8%)	 cases	 of	 re‑exploration	 among	 those	 with	
MCF	 ≥50	 mm	 (P	 =	 0.026).	 Need	 for	 inotropic	 agents	
in	 the	 operating	 room	 and	 the	 ICU	 did	 not	 show	 any	
statistically	 significant	 difference	 between	 the	 groups;	
however,	 the	 postoperative	 complications	 of	 the	 patients	
with	 MCF	 <50	 mm	 before	 CABG	 were	 fewer	 than	 those	
of	the	patients	with	MCF	of	50	mm	or	higher	(P	=	0.017).
The	 patients	 were	 also	 allocated	 to	 two	 subgroups	
according	 to	 their	 postoperative	 bleeding	 volumes:	 more	
and	 <1000	 mL.	 Fifty‑two	 patients	 had	 postoperative	
bleeding	 <1000	 mL,	 while	 postoperative	 bleeding	 in	
8	 patients	 exceeded	 that.	 The	 ROTEM®	 parameters	 in	
these	 two	 subgroups	 are	 displayed	 in	 Table	 3.	 Our	 data	
analyses	 showed	 significant	 statistical	 differences	 between	
the	patients	bleeding	<1000	mL	and	those	bleeding	at	 least	
1000	 mL	 vis‑à‑vis	 the	 ROTEM®	 parameters,	 comprising	
INTEM	α,	 EXTEM	MCF,	 EXTEM	α,	 INTEM	MCF,	 and	
HEPTEM	MCF	(all	Ps	<	0.05).
Discussion
Our	study	results	showed	that	EXTEM	MCF	<50	mm	in	the	
ROTEM®	 test	 in	patients	who	 received	 full	 dose	 (600	mg)	
of	 clopidogrel	 before	 CABG	 correlated	 with	 higher	 rates	
of	 postoperative	 bleeding,	 re‑exploration,	 complications,	
and	 need	 for	 blood	 product	 transfusion.	 We	 found	 that	
the	 patients	 who	 experienced	 postoperative	 bleeding	 of	
1000	mL	 or	more	 had	more	 complications	 and	were	more	
likely	 to	 undergo	 reoperation	 and	 require	 inotropic	 drugs.	
In	 addition,	 we	 observed	 associations	 between	 lower	
values	of	 the	ROTEM®	 test	parameters	 such	as	 INTEM	α,	
EXTEM	MCF,	EXTEM	α,	 INTEM	MCF,	HEPTEM	MCF,	
and	postoperative	bleeding	more	than	1000	mL.
In	 2010,	 approximately	 492,000	 PCI	 procedures	 were	
carried	 out	 in	 the	 United	 States.	 Researchers	 suggest	
that	 patients	 should	 be	 given	 the	 loading	 dose	 of	
clopidogrel	 (i.e.,	 600	 mg	 orally)	 and	 then	 75	 mg	 daily	
for	 2	months	 after	 PCI.[23]	Approximately	 15%	 of	 patients	
presenting	with	coronary	artery	disease	will	need	CABG	in	
the	future.[24]	On	the	other	hand,	it	is	well	known	that	more	
postoperative	 complications	 and	 higher	 blood	 transfusion	
rates	are	correlated	with	poor	outcomes.[25]
Clopidogrel	 is	 the	 main	 antiplatelet	 drug	 used	 after	 PCI;	
it	 should,	 nevertheless,	 be	 discontinued	 5–7	 days	 before	
surgery	 so	 that	 platelet	 activity	 reaches	 normal	 levels	 and	
the	 risk	 of	 intraoperative	 bleeding	 decreases.[26]	 Knowing	
the	 appropriate	 time	 to	 discontinue	 platelet	 receptor	
inhibitor	 drugs	 such	 as	 clopidogrel	 which	 block	 the	
P2Y12	receptor	 for	patients	who	undergo	CABG	is	crucial	
inasmuch	as	it	may	lessen	the	risk	of	bleeding	and	need	for	
massive	transfusion.[27,28]
Thromboelastograph	 (TEG®)	 demonstrates	 an	 integral	
evaluation	 for	 coagulation	 pathways	 and	 hemostasis.	
A	 study	 carried	out	 in	2010	 showed	 that	TEG®	 along	with	
platelet	mapping	(PM)	immediately	before	surgery	was	able	
to	 predict	 severe	 bleeding	 after	 surgery;	 furthermore,	 the	
authors	 of	 that	 article	 concluded	 that	 aspirin	 consumption	
did	 not	 affect	 postoperative	 bleeding.[29]	 Another	 study	
which	used	TEG‑PM®	in	patients	under	antiplatelet	therapy	
demonstrated	 more	 drainage	 from	 chest	 tubes	 in	 those	
using	 clopidogrel	 and	 there	 was	 a	 positive	 correlation	
between	 reductions	 in	 maximum	 amplitude	 ADP	 and	 a	
Table 1: Demographic characteristics and clinical 
variables data in the study groups
MCF <50 mm 
(n=16) (%)
MCF ≥50 mm 
(n=44) (%)
P
Gender
Male 16	(100) 38	(86.4) 0.179
Female 0 6	(13.6)
Age	(year) 60.56±7.38 61.11±10.58 0.849
Operating	room	
working	shift
Morning	8:00‑14:00 5	(31.3) 11	(25) 0.021
Evening	14:00‑19:00 1	(6.3) 19	(43.2)
Night	19:00‑8:00 10	(62.5) 14	(31.8)
Cigarette	smoking 7	(43.8) 19	(43.2) 1.000
Diabetes	mellitus 9	(56.3) 17	(38.6) 0.252
Dyslipidemia 1	(6.3) 19	(43.2) 0.011
Hypertension 3	(18.8) 31	(70.5) 0.001
Recent	myocardial	
infarction	(<1	months)
5	(31.3) 23	(52.3) 0.242
Nitrates 11	(68.8) 21	(47.7) 0.242
β‑blockers 12	(75) 28	(63.6) 0.567
Angiotensin‑converting	
enzyme	inhibitors
7	(43.8) 17	(38.6) 0.771
Aspirin 13	(81.3) 39	(88.6) 0.429
Proton	pump	inhibitors 3	(21.4) 3	(6.8) 0.145
Preoperative	ejection	
fraction
34.64±11.174 40.12±11.288 0.121
Mitral	regurgitation	
severity
No 7	(50) 25	(59.5) 0.793
Mild 5	(35.7) 13	(31)
Moderate 2	(14.3) 4	(9.5)
Severe 0 2	(14.3)
Number	of	vessels	
with	stenosis
2 0 2	(14.3) 1.000
3 6	(100) 12	(85.7)
All	data	are	expressed	as	means±SDs	or	n	(%).	MCF	in	the	
EXTEM	component	of	the	(ROTEM®)	test.	MCF:	Maximum	clot	
firmness,	EXTEM:	Extrinsically	activated	thromboelastometric,	
ROTEM:	Rotational	thromboelastometry,	SD:	Standard	deviation
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Table 2: Operative variables and postoperative complications in patients with maximum clot firmness <50 mm and 
≥50 mm
MCF <50 mm (%) MCF ≥50 mm (%) P
Aortic	cross‑clamp	time	(min) 43.75±7.41 48.68±28.79 0.504
Cardiopulmonary	bypass	time	(min) 81.44±15.16 88.03±41.44 0.0541
Operation	time	(h) 5.01±1.11 4.83±1.31 0.645
Chest	tube	drainage	6	h	after	ICU	
admission	(mL)
718.75±377.22 222.73±97.92 <0.0001
Chest	tube	drainage	12	h	after	ICU	
admission	(mL)
1031±547.08 338.1±106.96 <0.0001
Chest	tube	drainage	24	h	after	ICU	
admission	(mL)
1258.75±555.19 446.93±165.42 <0.0001
ICU	stay	(day) 8.29±3.99 4.32±2.25 <0.0001
Intubation	time	(h) 17.45±11.26 11.25±4.73 0.004
Packed	RBC	transfusion	in	the	OR	(units)
0 3	(18.8) 19	(43.2) 0.021
1 7	(43.8) 13	(29.5)
1< 6	(37.5) 13	(28.88)
FFP	transfusion	in	the	OR	(units)
0 3	(18.8) 27	(61.4) 0.003
1 0 6	(13.6)
1< 13	(81.25) 11	(25)
Platelet	transfusion	in	the	OR	(units)
0 6	(37.5) 22	(50) 0.175
1 1	(6.3) 5	(11.4)
1< 9	(56.25) 17	(38.63)
Packed	RBC	transfusion	in	the	ICU	(units)
0 2	(12.5) 20	(47.6) 0.005
1 6	(37.5) 12	(28.6)
>1 8	(50) 10	(23.80)
FFP	transfusion	in	the	ICU	(units)
0 9	(56.3) 37	(88.1) 0.013
1 0 0
>1 7	(43.75) 5	(11.90)
Platelet	transfusion	in	the	ICU	(units)
0 8	(50) 40	(92.5) <0.0001
1 2	(12.5) 0
>1 6	(37.5) 2	(4.76)
Re‑exploration 5	(31.3) 3	(6.8) 0.026
Postoperative	complications 6	(37.5) 4	(9.1) 0.017
Inotrope	use	in	the	OR 8	(50) 14	(31.8) 0.234
Inotrope	use	in	the	ICU 6	(37.5) 14	(31.8) 0.760
All	 data	 are	 expressed	 as	means±SDs	 or	n	 (%),	 >1:	More	 than	 one	 unit,	MCF	 in	 the	 EXTEM	 component	 of	 the	 (ROTEM®)	 test.	
EXTEM:	Extrinsically	activated	thromboelastometric,	ROTEM:	Rotational	thromboelastometry,	RBC:	Red	blood	cell,	FFP:	Fresh	frozen	
plasma,	ICU:	Intensive	Care	Unit,	OR:	Operating	room
higher	percentile	of	platelets	blocked.	In	that	study,	a	1	mm	
reduction	 in	 maximum	 amplitude	 ADP	 showed	 increased	
drainage	by	up	to	6%.[30]
Mahla	et	al.[31]	suggested	a	strategy	for	preoperative	platelet	
function	testing	to	time	CABG	in	a	better	manner	in	patients	
under	 clopidogrel	 therapy.	 In	 another	 study	 performed	 in	
2014,	 platelet	 inactivity	 measured	 by	 TEG‑PM®	 with	 a	
34%	cutoff	ADPPRI	(inhibition	of	adenosine	5‑diphosphate	
platelet	 receptor	 inhibition)	 was	 able	 to	 help	 prevent	
inappropriate	cancellation	of	surgeries.[32]	Görlinger	et	al.[33]	
concluded	 that	 given	 the	 ability	 of	 the	 ROTEM®	 analysis	
to	assess	heparin	effects	and	fibrinogen‑platelet	 interaction,	
this	 test	 was	 applicable	 to	 perioperative	 coagulation	
management	 for	 the	 monitoring	 of	 platelet	 function	 in	
cardiac	 patients.	 In	 addition,	 the	 authors	 reported	 that	
the	 ROTEM®	 test	 allowed	 a	 rapid	 evaluation	 of	 platelet	
function	and	prediction	of	postoperative	bleeding.
Serraino	 and	 Murphy	 discussed	 the	 use	 of	 “viscoelastic	
blood	 tests”	 for	 the	 management	 of	 coagulopathy	 in	
cardiac	 surgery	 patients	 and	 concluded	 that	 routine	 usage	
Azarfarin, et al.: ROTEM, clopidogrel, and post‑CABG bleeding
Annals of Cardiac Anaesthesia | Volume 21 | Issue 2 | April‑June 2018 179
of	viscoelastic	point‑of‑care	tests	did	not	decrease	mortality	
or	 complications.[34]	 This	 review,	 however,	 addressed	
“cardiac	 surgery	 patients”	 in	 general	 and	when	 faced	with	
a	 high	 risk	 subgroup	 of	 these	 patients,	 i.e.,	 those	 with	
unsuccessful	PCI,	having	taken	loading	dose	of	clopidogrel	
and	 undergoing	 emergency	 CABG,	 the	 clinical	 scenario	
may	be	somewhat	different.
New	 generations	 of	 ROTEM®	 test	 apparatus	 such	 as	
“ROTEM	 PM	 system”	 allow	 simultaneous	 analysis	
of	 thromboelastometry	 and	 platelet	 aggregation.	
These	 platelet	 aggregometry	 tests	 are	 Aratem	
(arachidonic	 acid),	 Traptem	 (thrombin‑activating	 peptide),	
and	 Adptem	 (ADP).[35]	 Furthermore,	 new	 techniques	 and	
simulators	help	anesthesiologists	to	train	medical	personnel	
with	essential	skills	to	face	the	real	clinical	scenarios.[36]
Conclusions
In	 summary,	we	 conclude	 that	when	platelet	 aggregometry	
is	 not	 available,	 the	ROTEM®	 analysis	 could	be	useful	 for	
the	prediction	of	increased	risk	of	bleeding	after	emergency	
CABG	 in	 patients	 on	 loading	 dose	 of	 clopidogrel.	
MCF	<50	mm	in	 the	EXTEM	component	of	 the	ROTEM®	
test	could	be	promising	 in	 the	 identification	and	evaluation	
of	coagulation	parameters	as	well	as	in	the	determination	of	
the	 appropriate	 time	 for	CABG	 in	 patients	 on	 clopidogrel.	
Nonetheless,	 further	 controlled	 and	 interventional	
(clinical	 trial)	 studies	 with	 larger	 sample	 sizes	 are	 needed	
to	confirm	this	relationship	strongly.
Limitations
The	 main	 limitation	 of	 the	 current	 study	 is	 its	
noninterventional	 design.	 We	 conducted	 only	 an	
observational	 research	 mainly	 considering	 ethical	 issues.	
Being	 fully	 aware	 that	 EXTEM	 MCF	 is	 the	 product	 of	
platelet	 function	 and	 fibrinogen	 activity,	 we	 included	 the	
FIBTEM	 analysis	 in	 the	 ROTEM®	 test	 to	 differentiate	
fibrin	 activity	 from	 platelet	 function	 although	 this	 is	
an	 indirect	 measurement .	 We	 did	 not	 measure	 plasma	
fibrinogen	levels.	Another	notable	weakness	of	our	work	is	
its	 limited	number	of	patients,	especially	 in	 the	group	with	
MCF	 <50	mm	 (n	 =	 16).	 The	main	 reason	 for	 this	 limited	
patient	 recruitment	 was	 difficulty	 in	 waiting	 and	 finding	
patients	who	were	 subjected	 to	 emergent	CABG	 following	
unsuccessful	primary	PCI.
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